Supernus' Trokendi XR deal delays Zydus generic to 2023

7 March 2017

Indian drugmaker Zydus Cadila has announced that it has finalized an agreement with the USA’s Supernus Pharmaceuticals (Nasdaq: SUPN) to settle all outstanding patent litigation related to Trokendi XR (topiramate) extended-release capsules.

Under the agreement, Supernus grants Zydus a licence to market a generic version of the capsules from January 1, 2023, or earlier under certain circumstances. Other terms of the settlement were not disclosed.

This is six years earlier than the expiration date of Supernus’ Trokendi XR patents, according to the company’s earlier litigation. On Tuesday, when the settlement was announced, the company's share price was down by 6.1% after 30 minutes of trading, at $27.92.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK